Results 191 to 200 of about 9,359 (237)
Some of the next articles are maybe not open access.
Expert Review of Clinical Pharmacology, 2022
Objectives Performing an updated meta-analysis to compare the safety and efficacy of insulin glargine and insulin detemir in adults with type 1 and type 2 diabetes. Methods Electronic databases were searched up to 18 August 2021.
S. Rezaei +5 more
semanticscholar +1 more source
Objectives Performing an updated meta-analysis to compare the safety and efficacy of insulin glargine and insulin detemir in adults with type 1 and type 2 diabetes. Methods Electronic databases were searched up to 18 August 2021.
S. Rezaei +5 more
semanticscholar +1 more source
Current Women's Health Reviews, 2022
Diabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women.
Seif Bugazia +9 more
semanticscholar +1 more source
Diabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women.
Seif Bugazia +9 more
semanticscholar +1 more source
Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes
Journal of pharmacy and practice, 2021Background: Prior research has demonstrated increased mortality with increasing glycemic variability (GV) in hospitalized patients with diabetes. Objective: We aimed to compare glycemic variability (GV) of insulin glargine to detemir in the inpatient ...
J. George +2 more
semanticscholar +1 more source
Iranian journal of pharmaceutical research, 2021
The aim of this study was to compare the insulin glargine and detemir effects on hormons affecting appetite and metabolic control of patients with type 1 diabetes.
M. Razzaghy-Azar +6 more
semanticscholar +1 more source
The aim of this study was to compare the insulin glargine and detemir effects on hormons affecting appetite and metabolic control of patients with type 1 diabetes.
M. Razzaghy-Azar +6 more
semanticscholar +1 more source
International Journal of Pharmaceutical Sciences and Nanotechnology
Background: Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder with rising global prevalence, imposing significant health and economic burdens.
Satish Gunda, V Jayashree
semanticscholar +1 more source
Background: Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder with rising global prevalence, imposing significant health and economic burdens.
Satish Gunda, V Jayashree
semanticscholar +1 more source
Journal of drug targeting (Print)
This trial evaluated the effects of insulin aspart (IAsp) and insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM).
Hui Wang +4 more
semanticscholar +1 more source
This trial evaluated the effects of insulin aspart (IAsp) and insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM).
Hui Wang +4 more
semanticscholar +1 more source
Hospital Pharmacy, 2005
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
American Journal of Health-System Pharmacy, 2020
PURPOSE In comparative randomized studies, use of insulin detemir has been consistently demonstrated to be associated with less weight gain than the industry standard, insulin glargine. However, the magnitude of the relative reduction in weight gain with
T. Wadsworth +4 more
semanticscholar +1 more source
PURPOSE In comparative randomized studies, use of insulin detemir has been consistently demonstrated to be associated with less weight gain than the industry standard, insulin glargine. However, the magnitude of the relative reduction in weight gain with
T. Wadsworth +4 more
semanticscholar +1 more source
Endocrine Practice, 2020
OBJECTIVE The cardiovascular outcomes of insulin detemir in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear.
TienâHsing Chen +7 more
semanticscholar +1 more source
OBJECTIVE The cardiovascular outcomes of insulin detemir in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear.
TienâHsing Chen +7 more
semanticscholar +1 more source
International journal of clinical pharmacology and therapeutics, 2020
OBJECTIVE This study aimed to compare the rate of hypoglycemic events from all spontaneously reported adverse events (AEs) between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System (KAERS) database.
DaWo Jeong, Won Kim, Ju-Young Shin
semanticscholar +1 more source
OBJECTIVE This study aimed to compare the rate of hypoglycemic events from all spontaneously reported adverse events (AEs) between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System (KAERS) database.
DaWo Jeong, Won Kim, Ju-Young Shin
semanticscholar +1 more source